TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Novo Nordisk ( (NVO) ) has provided an update.
On November 14, 2025, Novo Nordisk A/S held an Extraordinary General Meeting to elect new members to its Board of Directors. The meeting resulted in significant changes, including the election of Lars Rebien Sørensen as chair and Cees de Jong as vice chair, along with new board members Britt Meelby Jensen and Stephan Engels. These changes are aimed at supporting the company’s transformation plans to regain competitive leadership and ensure shareholder interests are addressed. The newly appointed board members will serve until the next Annual General Meeting in March 2026.
The most recent analyst rating on (NVO) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.
Spark’s Take on NVO Stock
According to Spark, TipRanks’ AI Analyst, NVO is a Outperform.
Novo Nordisk’s strong financial performance and reasonable valuation are key strengths, supporting a solid overall score. However, bearish technical indicators and challenges highlighted in the earnings call, such as market share loss and restructuring, weigh on the score. The company’s strategic focus on long-term growth and attractive dividend yield provide additional support.
To see Spark’s full report on NVO stock, click here.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. The company focuses on driving change to defeat serious chronic diseases, particularly through its heritage in diabetes. Novo Nordisk pioneers scientific breakthroughs, expands access to medicines, and works to prevent and ultimately cure diseases. It employs about 78,500 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange.
Average Trading Volume: 15,565,438
Technical Sentiment Signal: Sell
Current Market Cap: $222B
Find detailed analytics on NVO stock on TipRanks’ Stock Analysis page.